Clinical trials of adenoviruses in brain tumors: A review of Ad-p53 and oncolytic adenoviruses

Giacomo G. Vecil, Frederick F. Lang

Research output: Contribution to journalReview articlepeer-review

78 Scopus citations

Abstract

Adenoviruses have been critical in the development of the molecular approaches to brain tumors. They have been engineered to function as vectors for delivering therapeutic genes in gene therapy strategies, and as direct cytotoxic agents in oncolytic viral therapies. This review outlines the uses of adenoviruses in brain tumor therapy by examining clinical trials of adenovirus-mediated p53 gene therapy and by reviewing the application of two conditionally replicative adenoviruses (CRAds) ONYX-015 and Delta 24 in brain tumors. The potential clinical use of CRAds that deliver trangenes, particularly p53, is also discussed.

Original languageEnglish (US)
Pages (from-to)237-246
Number of pages10
JournalJournal of Neuro-Oncology
Volume65
Issue number3
DOIs
StatePublished - Dec 2003

Keywords

  • Adenovirus
  • Delta-24
  • Gene therapy
  • Glioblastoma
  • ONYX-015
  • P53

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical trials of adenoviruses in brain tumors: A review of Ad-p53 and oncolytic adenoviruses'. Together they form a unique fingerprint.

Cite this